Candidate dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes.

about

Candidate dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes.

Item

http://www.wikidata.org/entity/Q41918134

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Candidate dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes.

@en

type

Item

label

Candidate dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes.

@en

prefLabel

Candidate dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes.

@en

P1476

Candidate dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes.

@en

P2093

Dong-Lim Kim

http://www.w3.org/2001/XMLSchema#string

Yun-Mi Jang

http://www.w3.org/2001/XMLSchema#string

P2860

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

Standards of medical care in diabetes--2011.

Redefining the clinical management of type 2 diabetes: matching therapy to pathophysiology.

Predictive clinical parameters for the therapeutic efficacy of sitagliptin in korean type 2 diabetes mellitus

Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?

Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.

Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM.

Insulin secretory dysfunction and insulin resistance in the pathogenesis of korean type 2 diabetes mellitus.

Effect of sitagliptin plus metformin on β-cell function, islet integrity and islet gene expression in Zucker diabetic fatty rats.

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

P304

117-118

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.4093/DMJ.2011.35.2.117

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2011-04-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51476632

http://www.w3.org/2001/XMLSchema#string

P698

21738893

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

3122895

http://www.w3.org/2001/XMLSchema#string